Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1314 • 2015 ACR/ARHP Annual Meeting
Quantitative MRI Measurement of Tenosynovitis Demonstrates Differing Responses of Synovitis and Tenosynovitis after RA Treatment
Michael A. Bowes¹, Gwenael Guillard¹, Graham R. Vincent², Jane E. Freeston³, Edward M. Vital⁴, Paul Emery⁵ and Philip G. Conaghan⁶, ¹Imorphics, Manchester, United Kingdom, ²Imorphics Ltd, Manchester, United Kingdom, ³LIMM Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds Gen Infirmary, Leeds, United Kingdom, ⁶University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom
Background/Purpose: Inflammation of the tendon sheaths (tenosynovitis) is a recognised component of rheumatoid arthritis (RA). A comprehensive assessment of inflammation will require the inclusion of…
Abstract Number: 2270 • 2015 ACR/ARHP Annual Meeting
Cardiovascular Disease: The Hidden Risk in Persons with Rheumatoid Arthritis
Karen Soikkeli¹ and Glenn Ehresmann², ¹Graduate Nursing (Family Nurse Practitioner Program), Azusa Pacific University, Diamond Bar, CA, ²Rheumatology, Keck School of Medicine, University of Southern California-Los Angeles County Medical Center, Los Angeles, CA
Background/Purpose: Despite the fact that patients with rheumatoid arthritis (RA) experience a 50-60% increased risk of developing cardiovascular disease (CVD), substantial gaps remain in the…
Abstract Number: 2770 • 2015 ACR/ARHP Annual Meeting
Efficacy of Sarilumab Plus Methotrexate in Achieving Clinical Remission, Using 4 Different Definitions, in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis in a Phase 3 Study
Mark C. Genovese¹, Marina Stanislav², Hubert van Hoogstraten³, Renata Martincova⁴, Chunpeng Fan⁵ and Janet van Adelsberg⁶, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Research Institute of Rhumato, Moscow, Russia, ³Sanofi, Bridgewater, NJ, ⁴Sanofi Czech Republic, Prague, Czech Republic, ⁵Biostatistics, Sanofi, Bridgewater, NJ, ⁶Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY
Background/Purpose: Remission is an important clinical outcome in RA1 and is associated with improved physical function and health-related quality of life.2 Several definitions of remission…
Abstract Number: 176 • 2015 ACR/ARHP Annual Meeting
Considerable Discrepancy Between Patient’s Assessment and Ultrasonography Assessment on the Most Affected Joint in Rheumatoid Arthritis
Ryusuke Yoshimi¹, Yukihiro Toyota¹, Naomi Tsuchida¹, Yumiko Sugiyama¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Reikou Kamiyama¹, Kaoru Minegishi¹, Maasa Hama¹, Yohei Kirino¹, Mitsuhiro Takeno^1,2, Atsuhisa Ueda¹ and Yoshiaki Ishigatsubo^1,3, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, ³Center for Rheumatic Diseases, Yokosuka City Hospital, Yokosuka, Japan
Background/Purpose: Musculoskeletal ultrasonography (US) is a useful tool for the diagnosis and monitoring of rheumatoid arthritis (RA). It is also helpful for promoting patient-clinician communication…
Abstract Number: 1487 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis in Patients Who Have Failed to Disease-Modifying Antirheumatic Drugs: Long Term Results of the Brazilian Cohort
Wiliam Chahade¹, Cristiano Zerbini², Sebastiao Radominski³, Morton Scheinberg⁴, Walber P. Vieira⁵ and Ana Paula Garcia Lucco⁶, ¹Director-Rheumatology, Hospital Servidor Estadual, Sao Paulo, Brazil, ²Centro Paulista de Investigação Clinica, São Paulo, Brazil, ³Universidade Federal do Paraná, Curitiba, Brazil, ⁴Clinical Research, Hospital Abreu Sodre-AACD, Sao Paulo, Brazil, ⁵Hospital Geral de Fortaleza, Fortaleza, Brazil, ⁶Produtos Roche Químicos e Farmacêuticos SA, São Paulo, Brazil
Background/Purpose: Tocilizumab is a humanized monoclonal antibody that binds to IL-6 receptor, blocking its effects. The efficacy and safety of tocilizumab in rheumatoid arthritis (RA)…
Abstract Number: 2334 • 2015 ACR/ARHP Annual Meeting
Proof of Concept Study of the Arthritis Health Journal: An Online Tool to Promote Self-Monitoring in People with Rheumatoid Arthritis (RA)
Diane Lacaille^1,2, Erin Carruthers³, Brendan van As³, Charles H. Goldsmith^3,4, Hilary Horlock⁵, Linda Li^3,6, Anne F. Townsend^3,7, Beverly Mitchell⁸ and Paul Adam⁹, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁵Information Management / Information Technology Services, Provincial Health Services Authority, Vancouver, BC, Canada, ⁶Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ⁷Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, BC, Canada, ⁸Business Solutions and Collaboration, Provincial Health Services Authority, Vancouver, BC, Canada, ⁹Rheumatology Liaison, Mary Pack Arthritis Centre, Vancouver, BC, Canada
Background/Purpose: Patient passports have been used in chronic diseases to promote active involvement of patients in their care. In RA, patient monitoring of their disease…
Abstract Number: 3109 • 2015 ACR/ARHP Annual Meeting
Single Cell Gene Expression in Classical Monocytes Correlates with Treatment Response Groups to TNF-Alpha Inhibition in Rheumatoid Arthritis
Theresa Wampler Muskardin¹, Wei Fan², Jessica M. Dorschner³, Zhongbo Jin³, Mark A. Jensen⁴ and Timothy B. Niewold³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, China, Shanghai, China, ³Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: In management of rheumatoid arthritis (RA), initiating effective treatment as soon as possible within the so-called therapeutic “window of opportunity” is the strategy,…
Abstract Number: 433 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population
Machaon Bonafede¹, Jeffrey R. Curtis², Donna McMorrow¹, Chieh-I Chen³ and George J. Joseph⁴, ¹Truven Health Analytics, Cambridge, MA, ²Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ
Background/Purpose: A majority of RA patients who switch from a tumor necrosis factor inhibitor (TNFi) to another biologic disease-modifying anti-rheumatic drug (DMARD) are TNFi cyclers…
Abstract Number: 1529 • 2015 ACR/ARHP Annual Meeting
Trabecular Bone Score in Early Rheumatoid Arthritis
Eulalia Armengol¹, Helena Borrell Paños¹, Joan Miquel Nolla¹, Javier Narváez² and Carmen Gomez Vaquero¹, ¹Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is associated with low bone mass and increased risk of fragility fractures that are related to patient characteristics, treatments and disease…
Abstract Number: 2588 • 2015 ACR/ARHP Annual Meeting
Survivin Links Smoking and High Prevalence of Rheumatoid Arthritis in Women
Minna Turkkila¹, Apostolos Bossios², Malin Erlandsson³, Karin ME Andersson³, Sofia Töyrä Silfverswärd⁴, Maria Rolf⁵, Linda Ekerljung², Carina Malmhäll², Bo Lundbäck² and Maria Bokarewa⁶, ¹University of Göteborg, Göteborg, Sweden, ²The Krefting Research Centre, University of Gothenburg, Gothenburg, Sweden, ³Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Rheumatology and Inflammation Research, Gothenburg University, Gothenburg, Sweden, ⁵Department of Rheumatology and Inflammation Research University of Gothenburg, Gothenburg, Sweden, ⁶Rheumatology and Inflammation Research, Göteborgs University, Göteborg, Sweden
Background/Purpose : Patients with rheumatoid arthritis (RA) are predominantly female, smokers and positive for autoantibodies, rheumatoid factor and antibodies to citrullinated peptides. The oncoprotein survivin…
Abstract Number: 3199 • 2015 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis (RA) Patients, Retreatment with Rituximab (RTX) at Half Dose Does Not Alter Maintenance on Drug and Allows One Third Reduction of Cumulative Dose of Drug/Year: Data from the Autoimmunity and Rituximab (AIR) Registry
julien henry¹, stéphane pavy², Jacques Gottenberg³, rakiba belkhir⁴, Stéphanie Rouanet⁵, Jérémie Sellam⁶, Xavier Mariette⁷ and raphaèle seror⁴, ¹departement of rheumatology, Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ²rheumatology, Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ³Hautepierre, Strasbourg, France, ⁴Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ⁵Biostatistics, Roche France, Boulogne-Billancourt, France, ⁶Rheumatology and Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ⁷Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: In RA patients, different randomized clinical trials have showed that the efficacy of reduced dose of RTX either initially and for subsequent courses (DANCER,…
Abstract Number: 435 • 2015 ACR/ARHP Annual Meeting
Impact of Sarilumab on Fatigue, Pain, Morning Stiffness, Productivity, and Health Related Quality of Life (HRQoL) in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti-TNF-Î± Therapy: Results from a Phase 3 Study (RCT)
Vibeke Strand¹, Mark Kosinski², Neil Graham³, Chieh-I Chen³, George J. Joseph⁴, Deborah Bauer⁵, Yong Lin⁵, Cesar Pacheco-Tena⁶ and Roy Fleischmann⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²QualityMetric Inc, Lincoln, RI, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ⁷University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose : Sarilumab, a human monoclonal antibody directed against the IL-6 receptor, in combination with non-biologic DMARDs, demonstrated efficacy in the TARGET RCT (NCT01709578). TEAEs…
Abstract Number: 1543 • 2015 ACR/ARHP Annual Meeting
Traditional Risk Score Underestimates the Cardiovascular Risk in Rheumatoid Arthritis Patients
Tomas Cazenave¹, Natalia Zamora¹, Gustavo Citera^1,2 and Marcos G. Rosemffet¹, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina
Background/Purpose: An increased incidence of cardiovascular (CV) mortality has been reported in patients with rheumatoid arthritis (RA). Adequate stratification of the CV risk is an…
Abstract Number: 2591 • 2015 ACR/ARHP Annual Meeting
Ultrasound Residual Synovitis Has an Impact on the Time to Relapse in RA Patients Considered in Clinical Remission: A Real Life Study of 211 Patients
Pascal Zufferey¹, Myriam Riek², Giorgio Tamborrini³, Laure Brulhart⁴, Martin Toniolo⁵, Sandra Blumhardt⁶, Burkhard Moeller^7,8 and Hans Ruedi Ziswiler⁹, ¹Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland, ²SCQM Registry, Zurich, Switzerland, ³Rheumatologie, Bethesda spital, Basel, Switzerland, ⁴médecine, hôpital neuchateulois, La chaux de fond, Switzerland, ⁵Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁶rheumatology, USZ, zurich, Switzerland, ⁷Rheumatology, Inselspital-University Hospital, Bern, Switzerland, ⁸Rheumatology, Inselspital University Hospital, Bern, Switzerland, ⁹Osteorheuma, Bern, Switzerland
Background/Purpose: Previous publications have suggested that patients in clinical remission with residual ultrasound (US) synovitis flare more often and do not stay in remission as…
Abstract Number: 437 • 2015 ACR/ARHP Annual Meeting
Is Mode of Action Important When Switching Biologic Monotherapy in Rheumatoid Arthritis? Drug Adherence Results from the Swedish Ssatg Registry
Tanja Schjødt Jørgensen¹, Carl Turesson², Meliha C. Kapetanovic³, Martin Englund^4,5, Aleksandra Turkiewicz⁴, Robin Christensen¹, Henning Bliddal¹, Pierre Geborek³ and Lars Erik Kristensen¹, ¹The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology Lund University and Skåne University Hospital, Lund, Sweden, ⁴Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Clinical Epidemiology Unit, Orthopedics, Dept of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: About 30% of patients receiving biologic therapy do not have concomitant conventional synthetic DMARDs (csDMARDs). Little is known about the role of different mode…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].